In the Claims

1. (Currently Amended) A peptide comprising an amino acid sequence selected from ~~SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16,~~ SEQ ID NO:17, ~~SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36 or a truncated sequence thereof,~~ or between 9 and 14 consecutive amino acid residues of SEQ ID NO:17, and their pharmaceutically acceptable salts, wherein the peptide is characterized by a capacity to bind to transforming growth factor β1 (TGF-β1).

2. (Currently Amended) The peptide according to claim 1, ~~wherein the~~ comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36 ~~amino acid sequence is SEQ ID NO: 17, and truncated sequence thereof~~.

3. (Currently Amended) The peptide according to claim 1, characterized in that the peptide has the capacity to inhibit the biological activity of TGF-β1 *in vitro* and/or *in vivo*.

4. (Currently Amended) The method of making a pharmaceutical composition, said method comprising introducing the peptide of claim 1 into a pharmaceutically acceptable excipient ~~carrier~~.

5. (Currently Amended) The method of claim 4, wherein the pharmaceutical composition is useful for the treatment of diseases and pathological alterations associated with ~~modifies the~~ excessive or deregulated expression of TGF-β1 ~~due to a disease state~~.

6. (Currently Amended) The method of claim 5 [[4]], wherein the disease ~~state~~ comprises fibrosis associated with loss of function in an organ or tissue, surgical and/or aesthetic complications.

7. (Currently Amended) The method of claim 5 [[4]], wherein the disease ~~state~~ is selected from the group consisting of pulmonary fibrosis, hepatic fibrosis, [[(]]cirrhosis[[)]], renal fibrosis, cornea1 fibrosis,

fibrosis associated with skin and peritoneal surgery, fibrosis associated with burns, osteoarticular fibrosis and keloids.

8. (Currently Amended) A pharmaceutical composition comprising the peptide of claim 1 in ~~an~~ therapeutically effective amount ~~sufficient to bind to TGF-β1~~ and at least one pharmaceutically acceptable excipient.

9. (Currently Amended) The pharmaceutical composition of claim 8, further comprising one or more alternative TGF-β1 inhibiting compounds ~~selected from the group consisting of neutralizing antibodies, antisense oligonucleotide sequences of the gene encoding TGF-β1, and soluble receptors for TGF-β1~~.

10.-15. (Cancelled)

16. (Cancelled)

17. (Cancelled)

18. (Currently Amended) The peptide according to claim 1 [[2]], wherein the SEQ ID NO: 17 peptide is truncated ~~up to five amino acids~~ from its C terminal end.

19. (Currently Amended) The peptide according to claim 1, ~~wherein the peptide is~~ comprising the amino acid sequence ~~SEQ ID NO: 33 or~~ SEQ ID NO: 34.

20.-25. (Cancelled)

26. (Currently Amended) The peptide according to claim 2, characterized in that the peptide has the capacity to inhibit the biological activity of TGF-β1 *in vitro* and/or *in vivo*.

27. (Cancelled)

28. (New) The peptide according to claim 1, comprising the amino acid sequence SEQ ID NO: 35.

29. (New) The peptide according to claim 1, comprising the amino acid sequence SEQ ID NO: 36.

30. (New) The peptide according to claim 1, wherein the peptide comprises an amino acid sequence having between 9 and 14 consecutive amino acid residues of SEQ ID NO:17.

31. (New) A peptide comprising an amino acid sequence selected from SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, or SEQ ID NO:36, and their pharmaceutically acceptable salts, wherein the peptide is characterized by a capacity to bind to transforming growth factor β1 (TGF-β1).

32. (New) The peptide according to claim 1, wherein the SEQ ID NO: 17 peptide is truncated from its N terminal end.

33. (New) The peptide according to claim 1, comprising 9, 10, 11, 12, 13, or 14 consecutive amino acid residues of SEQ ID NO: 17.

34. (New) A peptide comprising an amino acid sequence selected from between 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive amino acid residues of SEQ ID NO:17, and their pharmaceutically acceptable salts, wherein the peptide is characterized by a capacity to bind to transforming growth factor β1 (TGF-β1).